Literature DB >> 3988901

Quantitation of hepatitis B virus (HBV) core antigen in serum in the presence of antibodies to HBV core antigen: comparison with assays of serum HBV DNA, DNA polymerase, and HBV e antigen.

R Bredehorst, H von Wulffen, C Granato.   

Abstract

A quantitation procedure for hepatitis B core antigen (HBcAg) in serum without prior removal of antibodies to HBcAg is described. The virus nucleoprotein core was released from hepatitis B virus (HBV) particles by treatment with Nonidet P-40 detergent and allowed to form immune complexes with homologous antibodies to HBcAg present in the sera of HBV-infected individuals. After precipitation with 2.0% polyethylene glycol-1.5% Tween 20, the HBcAg immune complexes were dissociated by treatment with 3 M KSCN and then adsorbed onto polystyrene beads in the presence of the SCN- ions. Thereby, HBcAg and antibodies to HBcAg were linked independently of each other to the matrix, and the core antigen could be quantitated directly by incubation of the beads with 125I-labeled anti-HBc. Even in the presence of an excess of antibodies to HBcAg in the polyethylene glycol precipitates, HBcAg could be detected without appreciably affecting the sensitivity. The assay proved to be specific for core determinants and exhibited excellent reproducibility. The application of the HBcAg assay in 185 hepatitis B e antigen-positive sera revealed HBc antigenemia in 99% of the sera containing hepatitis B e antigen at titers of greater than or equal to 1:256 and 43% of the sera with lower hepatitis B e antigen levels. However, only in 6 of the 34 HBcAg-negative sera could HBV DNA be detected by blot hybridization. When correlated with HBV-associated DNA polymerase (DNAP) activity, HBc antigenemia was found in all DNAP-positive sera (n = 95) and in 39% of the hepatitis B e antigen-positive sera without detectable DNAP activity (n = 44). Of the DNAP-negative sera with HBc antigenemia, 94% contained HBV DNA, whereas in the absence of HBcAg, HBV DNA could be detected only in 3 of 27 DNAP-negative sera. With regard to sensitivity, the HBcAg assay appeared to be less sensitive than the hybridization technique, but more sensitive than the DNAP assay.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3988901      PMCID: PMC271727          DOI: 10.1128/jcm.21.4.593-598.1985

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  23 in total

1.  Demonstration of hepatitis B e antigen (HBeAg) in association with intact Dane particles.

Authors:  H Ohori; S Onodera; N Ishida
Journal:  J Gen Virol       Date:  1979-05       Impact factor: 3.891

2.  Antigenic conversion from HBcAg to HBeAg by degradation of hepatitis B core particles.

Authors:  H Ohori; M Yamaki; S Onodera; E Yamada; N Ishida
Journal:  Intervirology       Date:  1980       Impact factor: 1.763

3.  Methodological approaches to antigen identification in soluble immune complexes; A model study.

Authors:  S Husby; S E Svehag; H Nielsen; N Høiby; P O Schiøtz
Journal:  Acta Pathol Microbiol Scand C       Date:  1981-04

4.  Quantitation of circulating immune complexes by combined PEG precipitation and immunoglobulin-specific radioimmunoassay (PICRIA).

Authors:  H C Siersted; I Brandslund; S E Svehag; J C Jensenius
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

5.  A radioimmunoassay for HBcAg in the sera of HBsAg carriers: serum HBcAg, liver HBcAg immunofluorescence as markers of chronic liver disease.

Authors:  M Rizzetto; J W Shih; G Verme; J L Gerin
Journal:  Gastroenterology       Date:  1981-06       Impact factor: 22.682

6.  Isolation of Dane particles containing a DNA strand by metrizamide density gradient.

Authors:  T Takahashi; K Kaga; Y Akahane; T Yamashita; Y Miyakawa; M Mayumi
Journal:  J Med Microbiol       Date:  1980-02       Impact factor: 2.472

7.  Demonstration and partial characterization of an intermediate HBcAG (Dane particle) population.

Authors:  G Hess; W Arnold; K H Meyer zum Büschenfelde
Journal:  J Med Virol       Date:  1981       Impact factor: 2.327

8.  Inhibition of hepatitis B virus specific DNA polymerase by intercalating agents.

Authors:  G Hess; W Arnold; B Möller; G M Gahl; K H Meyer zum Büschenfelde
Journal:  Med Microbiol Immunol       Date:  1980-02       Impact factor: 3.402

9.  The identification of specific antigens in circulating immune complexes by an enzyme-linked immunosorbent assay: detection of bovine kappa-casein IgG complexes in human sera.

Authors:  C Cunningham-Rundles
Journal:  Eur J Immunol       Date:  1981-06       Impact factor: 5.532

10.  Radioimmunoassay for hepatitis B core antigen.

Authors:  E Sagnelli; C Pereira; G Triolo; S Vernace; F Paronetto
Journal:  Clin Chem       Date:  1982-02       Impact factor: 8.327

View more
  10 in total

Review 1.  The underlying mechanisms for the "isolated positivity for the hepatitis B surface antigen (HBsAg)" serological profile.

Authors:  Robério Amorim de Almeida Pondé
Journal:  Med Microbiol Immunol       Date:  2010-05-11       Impact factor: 3.402

2.  Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load.

Authors:  Tatsuji Kimura; Akinori Rokuhara; Yoko Sakamoto; Shintaro Yagi; Eiji Tanaka; Kendo Kiyosawa; Noboru Maki
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

3.  New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA.

Authors:  Tatsuji Kimura; Akinori Rokuhara; Akihiro Matsumoto; Shintaro Yagi; Eiji Tanaka; Kendo Kiyosawa; Noboru Maki
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

4.  Protein composition of the hepatitis B virus e antigen in the natural course of disease and following interferon therapy.

Authors:  M L Campillo; J A Quiroga; J Bartolomé; G Moraleda; I Castillo; V Carreño
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

5.  Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection.

Authors:  Danny Ka-Ho Wong; Yasuhito Tanaka; Ching-Lung Lai; Masashi Mizokami; James Fung; Man-Fung Yuen
Journal:  J Clin Microbiol       Date:  2007-10-17       Impact factor: 5.948

Review 6.  Bacteriophages and their applications in the diagnosis and treatment of hepatitis B virus infection.

Authors:  Babak Bakhshinejad; Majid Sadeghizadeh
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 7.  Phage display creates innovative applications to combat hepatitis B virus.

Authors:  Wen Siang Tan; Kok Lian Ho
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

Review 8.  Atypical serological profiles in hepatitis B virus infection.

Authors:  Robério A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-29       Impact factor: 3.267

9.  RNA Interference inhibits hepatitis B virus of different genotypes in vitro and in vivo.

Authors:  Ya-Li Zhang; Tong Cheng; Yi-Jun Cai; Quan Yuan; Che Liu; Tao Zhang; De-Zhen Xia; Rui-Yin Li; Lian-Wei Yang; Ying-Bin Wang; Anthony E T Yeo; James Wai-Kuo Shih; Jun Zhang; Ning-Shao Xia
Journal:  BMC Microbiol       Date:  2010-08-10       Impact factor: 3.605

10.  A Dual Bioconjugated Virus-Like Nanoparticle as a Drug Delivery System and Comparison with a pH-Responsive Delivery System.

Authors:  Roya Biabanikhankahdani; Kok Lian Ho; Noorjahan Banu Alitheen; Wen Siang Tan
Journal:  Nanomaterials (Basel)       Date:  2018-04-13       Impact factor: 5.076

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.